PaxVax, Inc. Announces Positive Interim Results For Phase 3 Cholera Challenge Study; Clinical Trial Program To Proceed As Planned
1/9/2014 10:17:00 AM
MENLO PARK, Calif.--(BUSINESS WIRE)--PaxVax Inc, which develops and commercializes innovative vaccines against infectious diseases in a socially responsible manner, today announced interim data from a Phase 3 cholera challenge study of its single-dose oral cholera vaccine candidate, PXVX0200 (also known as CVD 103-HgR). Trial investigators compared the rate of diarrhea in participants vaccinated with PXVX0200 to the rate in participants who had received placebo. The vaccine appeared well tolerated. In an interim analysis of participants challenged at 10 days post vaccination with wild type, fully pathogenic cholera bacteria the rate of diarrhea was reduced in the vaccine group: 20 of 33 participants who received placebo experienced moderate-to-severe diarrhea compared to two of 35 participants who received PXVX0200.
Help employers find you! Check out all the jobs and post your resume.